NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
NCT03764917 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2020-03-24
Summary
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
Conditions
Interventions
- OTHER
-
Time
Different detecting time
Sponsors & Collaborators
-
Shanghai Pulmonary Hospital, Shanghai, China
lead OTHER
Principal Investigators
-
Yayi He, MD, PHD · Shanghai Pulmonary Hospital, Tongji University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-01
- Primary Completion
- 2020-12-31
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
NCT04777175 ·Status: RECRUITING
-
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
NCT05826483 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluate EGFR Mutation Status and Impact Factors in North China
NCT02620657 ·Status: COMPLETED
-
The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring
NCT04499794 ·Status: UNKNOWN
-
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
NCT04197076 ·Status: UNKNOWN
-
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719 ·Status: RECRUITING
-
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
NCT06951464 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
NCT04685070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT07122882 ·Status: ENROLLING_BY_INVITATION
-
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
NCT04671303 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
NCT01767974 ·Status: UNKNOWN
-
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
NCT03609918 ·Status: COMPLETED
-
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
NCT05165355 ·Status: UNKNOWN ·Phase: PHASE2
-
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
NCT06730503 ·Status: RECRUITING
-
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
NCT04304638 ·Status: UNKNOWN
-
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 ·Status: RECRUITING
-
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
NCT03808701 ·Status: UNKNOWN ·Phase: PHASE1
-
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg
NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
NCT04116918 ·Status: UNKNOWN
-
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
NCT04755738 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
NCT07177092 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
NCT06772610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
NCT02623257 ·Status: COMPLETED